HIV Biomarker Study for Natural and Treatment-Free Control
Part of Infections clinical trials.
This international study looks at blood samples from people with HIV to find markers that predict whether someone can control the virus without medication. It involves four groups: natural controllers, people who controlled virus after stopping treatment in a study, non-controllers (whose virus returns), and people stable on ART.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be living with HIV
- You either natural control HIV (viral load low without meds), or were part of a treatment interruption study, or are a non-controller (viral load goes up when off meds), or are on stable ART with suppressed virus
- For natural controllers: your viral load must have been under 400 copies/mL at least twice while off ART, with those tests 24 weeks apart
- For post-intervention controllers: you were in an ATI or MAP study and your viral load stayed low (under 400 copies/mL) for at least 8 weeks off ART
- For non-controllers: your viral load went above 1000 copies/mL after stopping treatment
- For suppressors: you have been on ART with viral load under 50 copies/mL and never had a rebound
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the hidden HIV 'reservoir' in people who naturally control the virus or who have controlled it after stopping treatment. It aims to understand why some people's immune systems can keep HIV in check, which could lead to new treatments.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
This study tests how well researchers can track HIV-related health and immune changes over time by collecting blood and other samples. It may help you and your care team by creating detailed monitoring, even if your HIV diagnosis is new or still being evaluated.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.